NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
NeOnc Technologies signed a nonbinding two-year Memorandum of Understanding with the Department of Health – Abu Dhabi covering oncology and CNS research collaboration, specialist training, and potential regional manufacturing or distribution activities. Two children in Abu Dhabi are receiving investigational NEO100 through the company's Compassionate Care program, with a third expected this week; a Phase 1 study in the Emirate is being worked toward, pending IRB approval. The release also recaps August's Phase 2a data, in which intranasal NEO100 hit a 48.9% six-month progression-free survival rate versus a 20% benchmark in recurrent IDH1-mutant high-grade glioma.
Key figures
- Drug Name
- NEO100
- Phase Of Trial
- Phase 2a
- Mou term
- two-year, nonbinding
- Short interest
- 757,739 shares (as of Sept 30)
- Phase2a pfs 6mo
- 48.9% vs 20% pre-specified benchmark (24-patient open-label study)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.